抗抑郁治疗药物的发病率与死亡率:2000-2014年美国毒物控制中心病例分析
该研究基于美国国家毒物数据系统(NPDS)2000-2014年12岁及以上人群的单药暴露报告,共纳入48种药物、962,222次单物质暴露。结果显示严重结局在15年间线性上升2.26倍,三环类与单胺氧化酶抑制剂发病率与死亡率均高,锂盐、喹硫平、奥氮平、安非他酮、卡马西平等新型药物亦显示较高风险。
要点
- 15年间抗抑郁相关药物单药暴露的严重结局上升2.26倍,呈线性趋势。
- 三环类与单胺氧化酶抑制剂发病率与死亡率均高,部分新型药物风险亦不容忽视。
- 锂盐、文拉法辛、安非他酮、喹硫平、奥氮平、齐拉西酮、丙戊酸、卡马西平、西酞普兰死亡率指数较高。
核心结论
- 抗抑郁治疗药物过量或非故意暴露后的严重结局在15年间显著上升,且不同药物间发病率与死亡率风险差异明显。
- 这些差异在为抑郁患者(尤其自杀风险增高者)选择治疗药物时具有重要参考价值。
研究设计与样本
- 研究查询美国国家毒物数据系统(NPDS),覆盖美国、波多黎各和哥伦比亚特区区域毒物中心的暴露报告。
- 纳入2000-2014年15年间12岁及以上个体的单药暴露,共48种药物、962,222次单物质暴露。
- 药物包括抗抑郁药、非典型抗精神病药、抗惊厥药、锂盐及其他用于抑郁治疗的药物。
- 主要结局为发病率指数(每1,000次暴露中严重结局数)与死亡率指数(每10,000次暴露中致命结局数)。
主要发现
- 15年间严重结局上升2.26倍,且呈线性方式增长。
- 三环类与单胺氧化酶抑制剂药物与高发病率和高死亡率相关。
- 锂盐、喹硫平、奥氮平、安非他酮、卡马西平与较高的发病率指数相关。
- 锂盐、文拉法辛、安非他酮、喹硫平、奥氮平、齐拉西酮、丙戊酸、卡马西平、西酞普兰与较高的死亡率指数相关。
关键数值与推荐
- 发病率指数定义为每1,000次暴露中严重结局的数量。
- 死亡率指数定义为每10,000次暴露中致命结局的数量。
- 研究共分析48种药物、962,222次单物质暴露,严重结局15年间上升2.26倍。
临床怎么用
- 为抑郁患者选药时可参考不同药物的发病率与死亡率风险差异,尤其对自杀风险增高者。
- 对死亡率指数较高的药物(如锂盐、文拉法辛、安非他酮、喹硫平、奥氮平、齐普拉西酮、丙戊酸、卡马西平、西酞普兰)应加强过量风险评估与用药监测。
- 三环类与单胺氧化酶抑制剂风险较高,临床选择时需权衡获益与安全性。
局限性
- 研究基于毒物中心暴露报告,可能存在报告偏倚与暴露信息不完整。
- 仅纳入单药暴露,未反映多药合并暴露或药物相互作用的实际风险。
- 发病率与死亡率指数为暴露相关指标,不能直接等同于临床治疗中的因果风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors sought to determine the relative morbidity and mortality associated with drugs used to treat depression and to examine specific clinical effects associated with serious outcomes. METHOD: The National Poison Data System, which receives exposure reports from regional poison centers serving the United States, Puerto Rico, and the District of Columbia, was queried for single drug exposures in individuals 12 years and older during the period 2000-2014. Medications included were antidepressants, atypical antipsychotics, anticonvulsants, lithium, and other medications used in the treatment of depression. The main outcomes were the morbidity index (the number of serious outcomes per 1,000 exposures) and the mortality index (the number of fatal outcomes per 10,000 exposures). RESULTS: During this 15-year period, there were 962,222 single substance exposures to the 48 medications studied. Serious outcomes rose 2.26-fold and in linear fashion over the 15 years. While tricyclic and monoamine oxidase inhibitor medications were associated with high morbidity and mortality, several newer agents also appeared hazardous. Lithium, quetiapine, olanzapine, bupropion, and carbamazepine were associated with high morbidity indices. Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic acid, carbamazepine, and citalopram were associated with higher mortality indices. CONCLUSIONS: Serious outcomes after overdose or nonintentional exposures to medications used to treat depression have risen dramatically over the past 15 years. The present data suggest that the morbidity and mortality risks vary substantially among these medications. These differences become important when selecting treatments for patients with depression, especially those at increased risk for suicide.
引用
- Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014. Am J Psychiatry. 2017. PMID: 28135844. doi:10.1176/appi.ajp.2016.16050523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。